Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation | Zendy

Jeffrey L. Anderson | Zendy; Benjamin D. Horne | Zendy; Scott M. Stevens | Zendy; Amanda Grove | Zendy; Stephanie Barton | Zendy; Zachery P. Nicholas | Zendy; Samera F.S. Kahn | Zendy; Heidi T. May | Zendy; Kent M. Samuelson | Zendy; Joseph B. Muhlestein | Zendy; John F. Carlquist | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation

Author(s) -

Jeffrey L. Anderson,

Benjamin D. Horne,

Scott M. Stevens,

Amanda Grove,

Stephanie Barton,

Zachery P. Nicholas,

Samera F.S. Kahn,

Heidi T. May,

Kent M. Samuelson,

Joseph B. Muhlestein,

John F. Carlquist

Publication year - 2007

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.107.737312

Subject(s) - medicine , dosing , pharmacogenetics , vkorc1 , warfarin , cyp2c9 , clinical endpoint , randomized controlled trial , pharmacology , anesthesia , genotype , atrial fibrillation , cytochrome p450 , metabolism , gene , biochemistry , chemistry

Pharmacogenetic-guided dosing of warfarin is a promising application of "personalized medicine" but has not been adequately tested in randomized trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research